BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

September 11, 2023

APHEXDA FDA Approval Press Release_09 11 23 - (Hebrew) (final).pdf 596.8 KB

Potential life-changing treatments are on the way

Each molecule in our development pipeline is carefully selected for its potential ability to improve upon the standard of care, delivering maximum value to patients

Discover our Pipeline

Release Details

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma